SEC filings and other documents

Expanding insurance coverage and sales force set the stage for rapid revenue growth in 2026-2027.

Q2 revenue up 116% YoY, gross margin at 85.9%, with payer coverage and VA expansion driving growth.

Record Q1 revenue and expanded coverage drive growth in pediatric and VA neuromodulation markets.

Neuromodulation therapies for GI disorders drive growth with FDA clearance and strong clinical data.

Q1 2026 revenue up 80% year-over-year, with margin and adoption gains in covered markets.

FDA-cleared neuromodulation device targets $22B+ GI market with strong clinical and payer support.

New CPT code and expanded coverage drive growth for a non-drug GI therapy with strong margins.

Double-digit revenue growth, expanded payer coverage, and strong commercial execution set stage for 2026.

Double-digit revenue growth continues as new CPT code and expanded indications set stage for 2026.

Guideline support and a new CPT code position IB-Stim for rapid growth in pediatric GI treatment.

Q2 2025 delivered 46% revenue growth and key milestones, setting up for accelerated expansion.

Strong clinical data, new CPT code, and expanded coverage set stage for rapid growth in 2025-26.

Q1 2025 saw 39% revenue growth, strong margins, and key milestones for future expansion.

Category one CPT code, expanded coverage, and strong data position for rapid growth in GI therapies.

Strong Q4 growth, expanded coverage, and key regulatory wins set stage for accelerated profitability.